Are all estrogens created equal?

Menopause

Volumn 11, Issue 1, 2004, Pages 7-8

  Eckler, Kristen ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRIOL; ESTROGEN RECEPTOR; ESTRONE;

ADULT; BONE DENSITY; BREAST CANCER; CANCER RISK; DRUG METABOLISM; DRUG RECEPTOR BINDING; DYSPAREUNIA; EDITORIAL; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; HIP FRACTURE; HORMONE RECEPTOR INTERACTION; HUMAN; INTERNET; MAJOR CLINICAL STUDY; PROGESTERONE BLOOD LEVEL; URINE INCONTINENCE; VAGINA ATROPHY; VASOMOTOR DISORDER; BREAST TUMOR; DRUG EFFECT; METABOLISM; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTMENOPAUSE; STRESS INCONTINENCE; URINARY TRACT INFECTION; UROGENITAL SYSTEM; VAGINA DISEASE;

BREAST NEOPLASMS; DYSPAREUNIA; ESTRIOL; FEMALE; HUMANS; POSTMENOPAUSE; URINARY INCONTINENCE, STRESS; URINARY TRACT INFECTIONS; UROGENITAL SYSTEM; VAGINAL DISEASES;

EID: 2442650694     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000103023.32049.FD     Document Type: Editorial

References (17)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
2. Dessole S, Rubattu G, Ambrosini G, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 2004;11:49-56.
3. Falconer C, Ekman-Ordeberg G, Ulmsten U, Westergren-Thorsson G, Barchan K, Malmstrom A. Changes in paraurethral connective tissue at menopause are counteracted by estrogen. Maturitas 1996;24:197-204.
4. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency: a pharmacokinetic and pharmacodynamic study. Maturitas 1992;15:121-127.
5. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the hormones and urogenital therapy committee. Obstet Gynecol 1994;83:12-18.
6. Jackson S, James M, Abrams P. The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence. BJOG 2002;109:339-344.
7. Robinson D, Cardozo L. The menopause and HRT. Urogenital effects of hormone therapy. Ballieres Best Pract Res Clin Endocrinol Metab 2003;17:91-104.
8. Taylor, M. Unconventional estogens: estriol, biest, and triest. Clin Obstet Gynecol 2001;44:864-879.
9. Schiff I, Wentworth B, Koos B, Ryan KJ, Tulchinsky D. Effect of estriol administration on the hypogonadal women. Fertil Steril 1978;30:278-282.
10. Speroff L, Glass R, Kase N. Clinical Gynecologic Endocrinology and Infertility, 6th ed. Baltimore, MD: Lippincott, Williams and Wilkins, 1999.
11. Lemon HM. Estriol prevention of mammary carcinoma induced by 7,12-dimethylbenzanthracene and procarbazine. Cancer Res 1975;35:1341-1353.
12. Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma [Review]. Acta Endocrinol Suppl (Copenh) 1980;233:17-27.
13. Dickinson LE, MacMahon B, Cole P, Brown JB. Estrogen profiles of Oriental and Caucasian women in Hawaii. N Engl J Med 1974;291:1211-1213.
14. Key TJ, Wang DY, Brown JB, et al. A prospective study of urinary oestrogen excretion and breast cancer risk. Br J Cancer 1996;73:1615-1619.
15. Takahashi K, Okada M, Ozaki T, et al. Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Hum Reprod 2000;15:1028-1036.
16. Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999;353:1824-1828.
17. Michaelsson K, Baron JA, Farahmand By, Ljunghall S. Use of low potency estrogens does not reduce the risk of hip fracture. Bone 2002;30:613-618.